Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | IL18 | Q14116 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL572710 | 0.83 | TSHR (0.52) | CA2CA9CA1PARP15PARP10 | |
| SCHEMBL10015246 | 0.82 | MEN1 (0.48) | CA2CA1KMT2AMEN1KDM4E | |
| SCHEMBL28757584 | 0.79 | CA2 (0.46) | CA2CA9CA1PARP15PARP10 | |
| SCHEMBL17512951 | 0.79 | CES2 (0.48) | CA2CA9CA1PARP15PARP10 | |
| SCHEMBL8055795 | 0.79 | SRC (0.54) | CA2CA9CA1PARP15PARP10 | |
| SCHEMBL11599743 | 0.76 | CYP2C19 (0.53) | CA2CA9CA1PARP15PARP10 | |
| Cyanophos-Oxon SCHEMBL17445283 | 0.76 | CYP3A4 (0.45) | CA2CA9CA1PARP15PARP10 | |
| SCHEMBL28460825 | 0.76 | MAOB (0.50) | CA2CA9CA1PARP15PARP10 | |
| SCHEMBL8805535 | 0.76 | CA1 (0.43) | CA2CA9CA1PARP15PARP10 | |
| SCHEMBL2354336 | 0.76 | MMP2 (0.44) | CA2CA9CA1PARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407447-B2 | Pantothenate derivatives for the treatment of neurological disorders | Retrophin, Inc. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180291045-A1 | PANTOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Retrophin, Inc. | 2018-10-11 | — | — | US | disclosed |
| EP-3060570-B1 | PANTOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | RETROPHIN INC (US) | 2018-09-19 | — | — | EP | disclosed |
| US-9896464-B2 | Pantothenate derivatives for the treatment of neurological disorders | Retrophin, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160264607-A1 | PANOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Retrophin, Inc. | 2016-09-15 | — | — | US | disclosed |
| EP-3060570-A1 | PANOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Retrophin, Inc. (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061792-A1 | PANOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Retrophin, Inc. (US) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407447-B2 | Pantothenate derivatives for the treatment of neurological disorders | PANK1, NADK, PANK2 | CA2 4376/4885CA9 4515/4885CA1 4454/4885 |
| US-20180291045-A1 | PANTOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PANK1, NADK, PANK2 | CA2 4376/4885CA9 4515/4885CA1 4454/4885 |
| US-20160264607-A1 | PANOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PANK1, PANK2, PANK3 | CA2 3719/4885CA9 3618/4885CA1 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.